Is Adeshwar Meditex overvalued or undervalued?

As of 29 August 2025, Adeshwar Meditex's valuation grade has moved from fair to attractive, indicating a positive shift in its market positioning. The company is currently deemed undervalued based on its financial metrics, with a Price to Earnings (PE) ratio of 12.79, an EV to EBITDA of 8.97, and a Price to Book Value of 0.76. These ratios suggest that Adeshwar Meditex is trading at a discount compared to its peers, particularly when compared to Poly Medicure, which has a PE ratio of 59.22, and Blue Jet Health, with a PE ratio of 32.28.
In the context of peer comparisons, Adeshwar Meditex stands out as attractive, especially when juxtaposed with companies like BPL, which is rated very attractive but has a significantly lower PE ratio of 6.97. Furthermore, the company's recent stock performance has outpaced the Sensex over the past week and month, with returns of 4.8% and 1.89% respectively, while the Sensex showed declines. This performance reinforces the notion that Adeshwar Meditex is undervalued in the current market landscape.